Reversal of growth failure in HIV-infected Thai children treated with non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy

AIDS Patient Care and STDs

Volumn 23, Issue 12, 2009, Pages 1067-1071

  Aurpibul, Linda ^a   Puthanakit, Thanyawee ^a   Taecharoenkul, Sineenart ^a   Sirisanthana, Thira ^a   Sirisanthana, Virat ^b  

^a CHIANG MAI UNIVERSITY   (Thailand)

^b Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ARTICLE; BODY HEIGHT; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CHILD; CONTROLLED STUDY; FEMALE; FOLLOW UP; GROWTH DISORDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PARAMETER; PRESCHOOL CHILD; PROBABILITY; PROPORTIONAL HAZARDS MODEL; PUBLIC HEALTH SERVICE; SCHOOL CHILD; THAILAND;

ADOLESCENT; ANTI-HIV AGENTS; BODY HEIGHT; CHILD; CHILD DEVELOPMENT; FEMALE; HIV INFECTIONS; HUMANS; MALE; REVERSE TRANSCRIPTASE INHIBITORS; THAILAND;

EID: 77149172823     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2009.0093     Document Type: Article

References (20)

1. Newell ML, Borja MC, Peckham C. Height, weight, and growth in children born to mothers with HIV-1 infection in Europe. Pediatrics 2003;111:e52-60.
2. Chantry CJ, Byrd RS, Englund JA, Baker CJ, McKinney RE, Jr. Growth, survival and viral load in symptomatic childhood human immunodeficiency virus infection. Pediatr Infect Dis J 2003;22:1033-1039.
3. Carey VJ, Yong FH, Frenkel LM, McKinney RE, Jr. Pediatric AIDS prognosis using somatic growth velocity. AIDS 1998; 12:1361-1369.
4. Puthanakit T, Oberdorfer A, Akarathum N, et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. Clin Infect Dis 2005;41:100-107.
5. Puthanakit T, Aurpibul L, Oberdorfer P, et al. Sustained immunologic and virologic efficacy after four years of highly active antiretroviral therapy in human immunodeficiency virus infected children in Thailand. Pediatr Infect Dis J 2007; 26:953-956.
6. Patel K, Hernan MA, Williams PL, et al. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: A 10-year follow-up study. Clin Infect Dis 2008;46:507-515. (Pubitemid 351263487)
7. Verweel G, van Rossum AMC, Hartwig NG, Wolfs TFW, Scherpbier HJ, de Groot R. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Pediatrics 2002;109:e25.
8. Nachman SA, Lindsey JC, Moye J, et al. Growth of human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2005;24: 352-357.
9. Guillen S, Ramos JT, Resino R, Bellon JM, Munoz MA. Impact on weight and height with the use of HAART in HIVinfected children. Pediatr Infect Dis J 2007;26:334-338.
10. Song R, Jelagat J, Dzombo D, et al. Efficacy of highly active antiretroviral therapy in HIV-1 Infected children in Kenya. Pediatrics 2007;120:e856-861.
11. Kabue MM, Kekitiinwa A, Maganda A, Risser JM, Chan W, Kline MW. Growth in HIV-infected children receiving antiretroviral therapy at a pediatric infectious diseases clinic in Uganda. AIDS Patient Care STDs 2008;22:245-251.
12. Working Group on Using Weight and Height References in Evaluating the Growth Status of Thai Children. Manual on Using Weight and Height References in Evaluation in Growth Status of Thai Children. Bangkok: Department of Health, Ministry of Public Health, 2000.
13. Lodha R, Upadhyay A, Kabra SK. Antiretroviral therapy in HIV-1 infected children. Indian Pediatr 2005;42:789-796.
14. Ble C, Floridia M, Muhale C, et al. Efficacy of highly active antiretroviral therapy in HIV-infected, institutionalized orphaned children in Tanzania. Acta Paediatr 2007;96:1090-1094.
15. Wamalwa DC, Farquhar C, Obimbo EM, et al. Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children. J Acquir Immune Defic Syndr 2007;45:311-317.
16. Janssens B, Raleigh B, Soeung S, et al. Effectiveness of highly active antiretroviral therapy in HIV-positive children: Evaluation at 12 months in a routine program in Cambodia. Pediatrics 2007;120:e1134-1140.
17. Kumarasamy N, Venkatesh KK, Devaleenol B, Poongulali S, Mothi SN, Solomon S. Safety, tolerability and effectiveness of generic HAART in HIV-infected children in South India. J Trop Pediatr 2009;55:155-159.
18. Jaspan HB, Berrisford AE, Boulle AM. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program. Pediatr Infect Dis J 2008;27:993-998.
19. AntiretroviraltherapyforHIVinfectionininfantsandchildren: Towards universal access. 2007. www.who.int=hiv=pub= guidelines=art=en=index.html (Last accessed April 19, 2009).
20. Manfredi R, Calza L, Chiodo F. Gynecomastia, lipodystrophy syndrome, and dyslipidemia occurring or worseng antiretroviral regimens other than protease inhibitor-based ones. J Acquir Immune Defic Syndr 2004;35:99-102.